Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GeneTx
Biotech
Ultragenyx ready to sign away $75M for Angelman partner GeneTx
A glimpse at data for just 11 patients was enough to convince Ultragenyx Pharmaceutical that GeneTx Biotherapeutics is worth $75 million.
Gabrielle Masson
Jul 18, 2022 10:16pm
Ultragenyx granted go-ahead to up doses for Angelman therapy
Jan 5, 2022 11:11am
Ultragenyx pauses trial after patients lose ability to walk
Oct 27, 2020 7:50am
Ultragenyx snags option on antisense startup GeneTx
Aug 15, 2019 9:20am
